Protein Phosphatase Magnesium-Dependent 1δ (PPM1D) mRNA Expression Is a Prognosis Marker for Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Li, Guang Bing ^a   Zhang, Xue Li ^a,b   Yuan, Li ^a   Jiao, Qi Qi ^a   Liu, De Jie ^c   Liu, Jun ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b Liaocheng People Hospital   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; ONCOPROTEIN; PROTEIN PHOSPHATASE MAGNESIUM DEPENDENT 1DELTA; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; FEMALE; GENDER; GENE EXPRESSION; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; PORTAL VEIN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHATASE MAGNESIUM DEPENDENT 1DELTA GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPROTEIN PHOSPHATASES; PROGNOSIS; RNA, MESSENGER; UP-REGULATION; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 84875487242     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060775     Document Type: Article

References (28)

1. Xu L, Qian G, Tang L, Su J, Wang JS, (2010) Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China. J Hepatol 53: 671-676.
2. Kishi Y, Hasegawa K, Sugawara Y, Kokudo N, (2011) Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol 2011: 728103.
3. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC, (2007) TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26: 2166-2176.
4. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC, (2003) TP53 and liver carcinogenesis. Hum Mutat 21: 201-216.
5. Mazzanti R, Gramantieri L, Bolondi L, (2008) Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med 29: 130-143.
6. Lim SO, Park YM, Kim HS, Quan X, Yoo JE, et al. (2011) Notch1 differentially regulates oncogenesis by wildtype p53 overexpression and p53 mutation in grade III hepatocellular carcinoma. Hepatology 53: 1352-1362.
7. Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, et al. (2008) The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 27: 123-135.
8. Shreeram S, Hee WK, Demidov ON, Kek C, Yamaguchi H, et al. (2006) Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J Exp Med 203: 2793-2799.
9. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, et al. (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31: 210-215.
10. Koom WS, Park SY, Kim W, Kim M, Kim JS, et al. (2012) Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma. J Radiat Res 53: 202-210.
11. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, et al. (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 36: 343-350.
12. Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, et al. (2008) Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol 86: 245-256.
13. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, et al. (2003) PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 63: 1876-1883.
14. Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, et al. (2007) Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 98: 392-400.
15. Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, et al. (2009) PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 15: 2269-2280.
16. Yu E, Ahn YS, Jang SJ, Kim MJ, Yoon HS, et al. (2007) Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers. Breast Cancer Res Treat 101: 269-278.
17. Rauta J, Alarmo EL, Kauraniemi P, Karhu R, Kuukasjarvi T, et al. (2006) The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat 95: 257-263.
18. Satoh N, Maniwa Y, Bermudez VP, Nishimura K, Nishio W, et al. (2011) Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival. Cancer Sci 102: 1101-1106.
19. Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, et al. (2008) Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9: 139-148.
20. Aravalli RN, Steer CJ, Cressman EN, (2008) Molecular mechanisms of hepatocellular carcinoma. Hepatology 48: 2047-2063.
21. Um TH, Kim H, Oh BK, Kim MS, Kim KS, et al. (2011) Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol 54: 939-947.
22. Jiang S, Yang Z, Li W, Li X, Wang Y, et al. (2012) Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesis. PLoS One 7: e40363.
23. Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, et al. (2005) Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 54: 1162-1168.
24. Ali AY, Abedini MR, Tsang BK, (2012) The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Oncogene 31: 2175-2186.
25. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, et al. (2004) High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 112: 44-50.
26. Yen YH, Changchien CS, Wang JH, Kee KM, Hung CH, et al. (2009) A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis 41: 431-441.
27. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M, (2007) Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 245: 909-922.
28. Lin SY, Pan HW, Liu SH, Jeng YM, Hu FC, et al. (2008) ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res 14: 4814-4820.